Joint involvement, including arthralgia, inflammatory arthritis, joint contractures and overlapping with rheumatoid arthritis, is a common manifestation and is associated with impared quality of life in systemic sclerosis (SSc). Few studies have evaluated the treatment of arthritis in SSc. Pharmacological approach includes low-dose corticosteroids, methotrexate, and hydroxychloroquine. Non-tumor necrosis factor biologics, especially rituximab and tocilizumab, may be a promising option for refractory cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2023.01.008 | DOI Listing |
Publication Analysis
Top Keywords
inflammatory arthritis
8
systemic sclerosis
8
treatment inflammatory
4
arthritis
4
arthritis systemic
4
sclerosis joint
4
joint involvement
4
involvement including
4
including arthralgia
4
arthralgia inflammatory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!